BÜHLMANN anti-SGPG autoantibodies ELISA Citations

US: BÜHLMANN GanglioCombi ELISA is for Research Use Only. Not for use in diagnostic procedures.
Health Canada Licence: 100436 and 100476
The citation list should be used for information only.

Herrendorff R et , 2017: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS, www.pnas.org/cgi/doi/10.1073/pnas.1619386114
DOI: 10.1073/pnas.1619386114

Caudie C et , 2007: [Diagnostic value of the anti-IgM SGPG Elisa (BÜHLMANN Laboratories AG) in 147 sera with a monoclonal IgM anti-MAG/SGPG antibody-associated neuropathy].
Ann Biol Clin (Paris) 65(4): 369-375
PMID: 17627917

The anti-SGPG autoantibody ELISA by BÜHLMANN turned out to be a very reliable commercially available
test with no technical difficulties and both, excellent sensitivity (0.98), and specificity (0.98)
for detecting MAG/SGPG antibody-mediated demyelinating neuropathies. Anti-SGPG
antibody titers have practical implications for both, management and follow-up of
neuropathies treated with rituximab.”

Bridel C et , 2014: Multifocal motor neuropathy with high titres of anti-MAG antibodies.
J Peripher Nerv Syst 19(2): 180-182
DOI: 10.1111/jns5.12069

Kuijf M et , 2009: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 73(9): 688-695
DOI: 10.1212/WNL.0b013e3181b59a80